Abstract
Immune checkpoint inhibitors inhibit the inhibitory mechanism on the immune system, their side effects may be autoimmune diseases that occur due to excessive immune response. Pembrolizumab is an immune checkpoint inhibitor targeting PD-1. The most common clinical presentations of thyroid injury induced by pembrolizumab are destructive thyroiditis and overt hypothyroidism. Herein, we presented a case of pembrolizumab induced hypothyroidism.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
